[go: up one dir, main page]

WO2003004622A3 - Human secreted proteins - Google Patents

Human secreted proteins Download PDF

Info

Publication number
WO2003004622A3
WO2003004622A3 PCT/US2002/008124 US0208124W WO03004622A3 WO 2003004622 A3 WO2003004622 A3 WO 2003004622A3 US 0208124 W US0208124 W US 0208124W WO 03004622 A3 WO03004622 A3 WO 03004622A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptides
present
human secreted
polynucleotides
encompassed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/008124
Other languages
French (fr)
Other versions
WO2003004622A2 (en
Inventor
Craig A Rosen
Steven M Ruben
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Priority to EP02782476A priority Critical patent/EP1414845A4/en
Priority to CA002441416A priority patent/CA2441416A1/en
Priority to AU2002354719A priority patent/AU2002354719A1/en
Publication of WO2003004622A2 publication Critical patent/WO2003004622A2/en
Priority to US10/664,357 priority patent/US20070055056A1/en
Anticipated expiration legal-status Critical
Publication of WO2003004622A3 publication Critical patent/WO2003004622A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention relates to human secreted polypeptides, and isolated nucleic acid molecules encoding said polypeptides, useful for diagnosing and treating diabetes mellitus and/or conditions related to diabetes. Antibodies that bind these polypeptides are also encompassed by the present invention. Also encompassed by the invention are vectors, host cells, and recombinant and synthetic methods for producing said polynucleotides, polypeptides, and/or antibodies. The invention further encompasses screening methods for identifying agonists and antagonists of, polynucleotides and polypeptides of the invention. The present invention further encompasses methods and compositions for inhibiting or enhancing the production and function of the jpolypeptides of the present invention.
PCT/US2002/008124 1997-03-07 2002-03-19 Human secreted proteins Ceased WO2003004622A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP02782476A EP1414845A4 (en) 2001-03-21 2002-03-19 Human secreted proteins
CA002441416A CA2441416A1 (en) 2001-03-21 2002-03-19 Human secreted proteins
AU2002354719A AU2002354719A1 (en) 2001-03-21 2002-03-19 Human secreted proteins
US10/664,357 US20070055056A1 (en) 1997-03-07 2003-09-20 251 human secreted proteins

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US27734001P 2001-03-21 2001-03-21
US60/277,340 2001-03-21
US30617101P 2001-07-19 2001-07-19
US60/306,171 2001-07-19
US33128701P 2001-11-13 2001-11-13
US60/331,287 2001-11-13

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US09/981,876 Continuation-In-Part US7053190B2 (en) 1997-03-07 2001-10-19 Secreted protein HRGDF73
US10/100,683 Continuation-In-Part US7368531B2 (en) 1997-03-07 2002-03-19 Human secreted proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/664,357 Continuation-In-Part US20070055056A1 (en) 1997-03-07 2003-09-20 251 human secreted proteins

Publications (2)

Publication Number Publication Date
WO2003004622A2 WO2003004622A2 (en) 2003-01-16
WO2003004622A3 true WO2003004622A3 (en) 2004-02-19

Family

ID=27402891

Family Applications (7)

Application Number Title Priority Date Filing Date
PCT/US2002/009785 Ceased WO2002095010A2 (en) 1997-03-07 2002-03-19 Human secreted proteins
PCT/US2002/008124 Ceased WO2003004622A2 (en) 1997-03-07 2002-03-19 Human secreted proteins
PCT/US2002/008278 Ceased WO2002102994A2 (en) 1997-03-07 2002-03-19 Human secreted proteins
PCT/US2002/008123 Ceased WO2002102993A2 (en) 1997-03-07 2002-03-19 Human secreted proteins
PCT/US2002/008276 Ceased WO2002076488A1 (en) 1997-03-07 2002-03-19 Human secreted proteins
PCT/US2002/008277 Ceased WO2003038063A2 (en) 2001-03-21 2002-03-19 Human secreted proteins
PCT/US2002/008279 Ceased WO2002090526A2 (en) 1997-03-07 2002-03-19 Human secreted proteins

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2002/009785 Ceased WO2002095010A2 (en) 1997-03-07 2002-03-19 Human secreted proteins

Family Applications After (5)

Application Number Title Priority Date Filing Date
PCT/US2002/008278 Ceased WO2002102994A2 (en) 1997-03-07 2002-03-19 Human secreted proteins
PCT/US2002/008123 Ceased WO2002102993A2 (en) 1997-03-07 2002-03-19 Human secreted proteins
PCT/US2002/008276 Ceased WO2002076488A1 (en) 1997-03-07 2002-03-19 Human secreted proteins
PCT/US2002/008277 Ceased WO2003038063A2 (en) 2001-03-21 2002-03-19 Human secreted proteins
PCT/US2002/008279 Ceased WO2002090526A2 (en) 1997-03-07 2002-03-19 Human secreted proteins

Country Status (4)

Country Link
EP (7) EP1414845A4 (en)
AU (6) AU2002332391A1 (en)
CA (7) CA2441417A1 (en)
WO (7) WO2002095010A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7319006B2 (en) 1998-06-01 2008-01-15 Genentech, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US9617346B2 (en) 2004-04-22 2017-04-11 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US11180571B2 (en) 2017-04-03 2021-11-23 Hoffmann-La Roche Inc. Antibodies binding to STEAP-1

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196164B2 (en) 1997-07-08 2007-03-27 Human Genome Sciences, Inc. Secreted protein HHTLF25
JP2002513295A (en) 1997-07-08 2002-05-08 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド 123 human secreted proteins
DK1086223T3 (en) 1998-06-01 2009-11-30 Agensys Inc Novel serpentine transmembrane antigens expressed in human cancers and their applications
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US20040141975A1 (en) 1998-06-01 2004-07-22 Raitano Arthur B. Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US20060052321A1 (en) 2002-04-05 2006-03-09 Raitano Arthur B Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
EP1141027A1 (en) 1999-01-15 2001-10-10 Biogen, Inc. Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
US7335731B2 (en) 2000-07-25 2008-02-26 Genentech, Inc. PRO4332 polypeptides
EP1666490A3 (en) * 2000-07-25 2006-11-02 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2004528823A (en) 2000-10-31 2004-09-24 ディアデクサス インコーポレーテッド Compositions and methods for colon-specific genes and proteins
US20020111302A1 (en) * 2000-11-30 2002-08-15 Y. Tom Tang Novel nucleic acids and polypeptides
US7736654B2 (en) 2001-04-10 2010-06-15 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
US20030100497A1 (en) 2001-06-20 2003-05-29 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
ES2532757T3 (en) 2001-09-06 2015-03-31 Agensys, Inc. Nucleic acid and corresponding protein called STEAP-1 useful in the treatment and detection of cancer
US7097990B2 (en) 2001-10-12 2006-08-29 Astellas Pharma Inc. Method of screening cell death inhibitor
CN102793921A (en) 2002-04-09 2012-11-28 比奥根艾迪克Ma公司 Methods for treating tweak-related conditions
AU2003900747A0 (en) * 2003-02-18 2003-03-06 Garvan Institute Of Medical Research Diagnosis and treatment of pancreatic cancer
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
WO2005019258A2 (en) * 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP1842920B2 (en) * 2003-09-23 2017-06-21 University Of North Carolina At Chapel Hill Cells coexpressing vitamin K reductase and vitamin K dependent protein and use thereof to improve the productivity of said vitamin K dependent protein
EP2272951B1 (en) * 2003-10-14 2014-07-23 Baxter International Inc. Vitamin k epoxide recycling polypeptide vkorc1, a therapeutic target of coumarin and their derivatives
US20070269421A1 (en) * 2004-02-03 2007-11-22 Bayer Healthcare Ag Diagnostics and Therapeutics for Diseases Associated with Plasma Glutamate Carboxypeptidase (Pgcp)
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
CA2578775C (en) * 2004-09-01 2016-05-03 Dynavax Technologies Corporation Methods and compositions for inhibition of innate immune responses and autoimmunity
EP1799849A4 (en) * 2004-09-07 2008-07-09 Telethon Inst For Child Health AGENTS FOR THE TREATMENT OR PREVENTION OF ALLERGIC DISEASES
EP1799850A4 (en) * 2004-09-07 2009-02-11 Telethon Inst For Child Health METHOD OF DIAGNOSING AND / OR PREDICTING DEVELOPMENT OF ALLERGIC DISEASE
EP1859277A4 (en) 2005-02-17 2010-03-17 Biogen Idec Inc Treating neurological disorders
MX2007010489A (en) 2005-02-28 2007-11-08 Baxter Int Recombinant co-expression of vitamin k epoxide reductase subunit 1 to improve vitamin k dependent protein expression.
JP2008532544A (en) 2005-03-15 2008-08-21 ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル Methods and compositions for producing active vitamin K-dependent proteins
JP5339901B2 (en) 2005-05-10 2013-11-13 バイオジェン・アイデック・エムエイ・インコーポレイテッド Treatment and evaluation of inflammatory injury
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
CA2620809A1 (en) * 2005-09-01 2007-03-08 Howard Florey Institute Of Experimental Physiology And Medicine Prophylactic and therapeutic agents and uses therefor
GB0521488D0 (en) * 2005-10-21 2005-11-30 Ares Trading Sa Integral membrane protein
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
HUE034263T2 (en) 2006-10-27 2018-02-28 Genentech Inc Antibodies and immunoconjugates and uses therefor
WO2008057459A2 (en) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonists of pcsk9
US8093222B2 (en) * 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
CA2680832A1 (en) 2007-03-27 2008-10-02 Merck & Co., Inc. Method for detecting autoprocessed, secreted pcsk9
JOP20080381B1 (en) 2007-08-23 2023-03-28 Amgen Inc Antigen Binding Proteins to Proprotein Convertase subtillisin Kexin type 9 (pcsk9)
EP2361980B1 (en) 2007-10-26 2016-12-07 Dynavax Technologies Corporation Methods and compositions for inhibition of immune responses and autoimmunity
CN101932728B (en) * 2007-11-30 2013-06-19 西门子医疗保健诊断公司 Adiponectin receptor fragments and methods of use
AR070315A1 (en) 2008-02-07 2010-03-31 Merck & Co Inc ANTIBODIES 1B20 ANTAGONISTS OF PCSK9
AR070316A1 (en) 2008-02-07 2010-03-31 Merck & Co Inc PCSK9 ANTAGONISTS (SUBTILISINE-KEXINA TYPE 9 PROPROTEIN)
US8748115B2 (en) 2008-12-12 2014-06-10 Merck Sharp & Dohme Corp. PCSK9 immunoassay
CN102596249A (en) 2009-10-30 2012-07-18 默沙东公司 AX1 and AX189 PCSK9 antagonists and variants
WO2011053783A2 (en) 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Ax213 and ax132 pcsk9 antagonists and variants
US8940310B2 (en) 2010-06-16 2015-01-27 Dynavax Technologies Corporation Methods of treatment using TLR7 and/or TLR9 inhibitors
CN103209987B (en) 2010-09-22 2017-06-06 艾丽奥斯生物制药有限公司 substituted nucleotide analogs
US9631002B2 (en) 2010-12-21 2017-04-25 The University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin K-dependent proteins
HK1203075A1 (en) 2011-12-22 2015-10-16 艾丽奥斯生物制药有限公司 Substituted phosphorothioate nucleotide analogs
NZ631601A (en) 2012-03-21 2016-06-24 Alios Biopharma Inc Solid forms of a thiophosphoramidate nucleotide prodrug
WO2013142157A1 (en) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9051378B1 (en) 2014-07-15 2015-06-09 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9682218B2 (en) 2013-12-23 2017-06-20 Carefusion 2200, Inc. Pleurodesis device and method
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
KR102531889B1 (en) 2016-06-20 2023-05-17 키맵 리미티드 Anti-PD-L1 and IL-2 cytokines
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
IL318866A (en) 2016-12-23 2025-04-01 Harvard College Gene editing of pcsk9 and related methods, compositions, and uses thereof
WO2018237213A1 (en) 2017-06-22 2018-12-27 The Procter & Gamble Company FILMS COMPRISING A WATER-SOLUBLE LAYER AND AN INORGANIC COATING PRESENTED IN STEAM PHASE
ES2963042T3 (en) 2017-06-22 2024-03-25 Procter & Gamble Films that include a water-soluble layer and an organic vapor-deposited coating
MX2022012683A (en) 2020-04-09 2023-01-11 Verve Therapeutics Inc Base editing of pcsk9 and methods of using same for treatment of disease.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013773A (en) * 1996-02-02 2000-01-11 Mitsui Chemicals, Inc. Pharmaceutical preparation containing human growth hormone

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002026931A2 (en) * 2000-09-25 2002-04-04 Human Genome Sciences, Inc. 71 human secreted proteins
US5858716A (en) * 1997-05-30 1999-01-12 Smithkline Beecham Corporation H2CAA71 polynucleotides
CA2333917A1 (en) * 1998-07-15 2000-01-27 Human Genome Sciences, Inc. 71 human secreted proteins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013773A (en) * 1996-02-02 2000-01-11 Mitsui Chemicals, Inc. Pharmaceutical preparation containing human growth hormone

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1414845A4 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7319006B2 (en) 1998-06-01 2008-01-15 Genentech, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US9617346B2 (en) 2004-04-22 2017-04-11 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US10597463B2 (en) 2004-04-22 2020-03-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US11401347B2 (en) 2004-04-22 2022-08-02 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US11180571B2 (en) 2017-04-03 2021-11-23 Hoffmann-La Roche Inc. Antibodies binding to STEAP-1
US11685790B2 (en) 2017-04-03 2023-06-27 Hoffmann-La Roche Inc. Antibodies binding to STEAP-1
US12129306B2 (en) 2017-04-03 2024-10-29 Hoffman-La Roche Inc. Antibodies binding to STEAP-1

Also Published As

Publication number Publication date
AU2002324424A1 (en) 2002-12-03
EP1414845A2 (en) 2004-05-06
AU2002332391A1 (en) 2003-01-02
WO2003004622A2 (en) 2003-01-16
WO2002102994A2 (en) 2002-12-27
CA2441416A1 (en) 2003-01-16
WO2002095010A3 (en) 2004-02-12
WO2002090526A2 (en) 2002-11-14
EP1423134A2 (en) 2004-06-02
EP1404702A4 (en) 2009-07-08
CA2441417A1 (en) 2002-11-14
EP1379264A4 (en) 2009-07-08
CA2441832A1 (en) 2002-12-27
EP1379132A4 (en) 2009-07-01
CA2441702A1 (en) 2002-12-27
EP1379264A1 (en) 2004-01-14
EP1414845A4 (en) 2009-07-08
EP1379132A2 (en) 2004-01-14
WO2003038063A3 (en) 2003-12-11
AU2002363296A1 (en) 2003-05-12
EP1390390A2 (en) 2004-02-25
CA2441840A1 (en) 2002-11-28
WO2002076488A1 (en) 2002-10-03
EP1390390A4 (en) 2009-07-08
AU2002354719A1 (en) 2003-01-21
AU2002326293A1 (en) 2003-01-02
WO2003038063A2 (en) 2003-05-08
EP1381622A2 (en) 2004-01-21
WO2002102993A2 (en) 2002-12-27
EP1404702A2 (en) 2004-04-07
WO2002102994A3 (en) 2003-07-24
WO2002095010A2 (en) 2002-11-28
AU2002320013A1 (en) 2002-11-18
CA2441397A1 (en) 2002-10-03
WO2002102993A3 (en) 2004-03-25
CA2441755A1 (en) 2003-05-08
WO2002090526A3 (en) 2003-10-30

Similar Documents

Publication Publication Date Title
WO2003004622A3 (en) Human secreted proteins
WO2003000865A3 (en) Human secreted proteins
WO2001055322A8 (en) Nucleic acids, proteins, and antibodies
WO2001090304A3 (en) Nucleic acids, proteins, and antibodies
WO2001054472A3 (en) Nucleic acids, proteins, and antibodies
WO2001055306A3 (en) Nucleic acids, proteins, and antibodies
WO2001055326A8 (en) Nucleic acids, proteins, and antibodies
WO2004042000A3 (en) 157 human secreted proteins
WO2001055168A8 (en) Nucleic acids, proteins and antibodies
WO2001055440A8 (en) Nucleic acids, proteins, and antibodies
WO2002072763A3 (en) Nucleic acids, proteins, and antibodies
WO2001055167A8 (en) Nucleic acids, proteins, and antibodies
WO2001055162A8 (en) Nucleic acids, proteins, and antibodies
WO2001055305A3 (en) Nucleic acids, proteins, and antibodies

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 10664357

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2441416

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002782476

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2002782476

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 10664357

Country of ref document: US